GlaxoSmithKline
GSK
#209
Rank
S$126.63 B
Marketcap
S$62.73
Share price
-0.33%
Change (1 day)
40.32%
Change (1 year)

GlaxoSmithKline (GSK) - Cash on Hand

Cash on Hand as of September 2025 : S$5.75 Billion

According to GlaxoSmithKline's latest financial reports the company has S$5.75 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

GlaxoSmithKline - Cash on Hand chart (from 1996 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31S$6.33 B-24.58%
2023-12-31S$8.39 B-32.54%
2022-12-31S$12.45 B65.01%
2021-12-31S$7.54 B-32.18%
2020-12-31S$11.12 B37.23%
2019-12-31S$8.10 B18.12%
2018-12-31S$6.86 B-2.91%
2017-12-31S$7.06 B-20.6%
2016-12-31S$8.90 B-28.07%
2015-12-31S$12.37 B36.53%
2014-12-31S$9.06 B-22.53%
2013-12-31S$11.70 B38.83%
2012-12-31S$8.43 B-28.99%
2011-12-31S$11.87 B-4.34%
2010-12-31S$12.41 B-21.31%
2009-12-31S$15.77 B9.52%
2008-12-31S$14.39 B11.03%
2007-12-31S$12.96 B42.09%
2006-12-31S$9.12 B-39.25%
2005-12-31S$15.02 B20.61%
2004-12-31S$12.45 B18.78%
2003-12-31S$10.48 B52.68%
2002-12-31S$6.86 B10.24%
2001-12-31S$6.23 B-32.94%
2000-12-31S$9.29 B75.67%
1999-12-31S$5.28 B2.21%
1998-12-31S$5.17 B12.42%
1997-12-31S$4.60 B52.21%
1996-12-31S$3.02 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
AstraZeneca
AZN
S$10.60 B 84.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
S$19.41 B 237.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
S$23.60 B 309.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
S$12.63 B 119.45%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$13.54 B 135.17%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
S$2.85 B-50.43%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Dynavax Technologies
DVAX
S$0.83 B-85.42%๐Ÿ‡บ๐Ÿ‡ธ USA